Skip to main content
Top
Published in: Drug Safety 10/2007

01-10-2007 | Abstracts

Poster Presentations

Authors: M. Tuccori, U. Moretti, F. Lapi, D. Coli, A. Testi, M. Moschini, A. Vannacci, C. Blandizzi, A. Mugelli, M. Del Tacca

Published in: Drug Safety | Issue 10/2007

Login to get access

Excerpt

Background: Statins are widely prescribed hypolipidaemic drugs. Since lipids account for half of the dry matter of central nervous system (CNS) and are integral to myelin sheaths and synapses, recent interest was risen on potential psychiatric side effects of statins[1] including memory loss, depression, suicidality, aggression and antisocial behaviour. [2]
Literature
1.
go back to reference Parale GP, Baheti NN, Kulkarni PM, et al. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol 2006; 6: 259–65CrossRef Parale GP, Baheti NN, Kulkarni PM, et al. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol 2006; 6: 259–65CrossRef
2.
go back to reference Tatley M, Savane R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implication for the use of lipid-lowering agents. Drug Saf 2007; 30: 195–201PubMedCrossRef Tatley M, Savane R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implication for the use of lipid-lowering agents. Drug Saf 2007; 30: 195–201PubMedCrossRef
3.
go back to reference Suribhatla S, Dennis MS, Potter JF. A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. J Neurol Sci 2005; 229: 147–50PubMedCrossRef Suribhatla S, Dennis MS, Potter JF. A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. J Neurol Sci 2005; 229: 147–50PubMedCrossRef
Metadata
Title
Poster Presentations
Authors
M. Tuccori
U. Moretti
F. Lapi
D. Coli
A. Testi
M. Moschini
A. Vannacci
C. Blandizzi
A. Mugelli
M. Del Tacca
Publication date
01-10-2007
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2007
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200730100-00061

Other articles of this Issue 10/2007

Drug Safety 10/2007 Go to the issue